The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
An update on the diagnosis and treatment of Parkinson disease
Open accessAbstract
Parkinson disease is the second most common neurodegenerative disorder after Alzheimer disease.[1][1] Parkinson disease typically develops between the ages of 55 and 65 years and occurs in 1%–2% of people over the age of 60 years, rising to 3.5% at age 85–89 years.[2][2]–[4][3] About 0.3% of
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Parallel organization of functionally segregated circuits linking basal ganglia and cortex
Alexander, G. E., DeLong, M. R., & Strick, P. L. (1986) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.09.030186.002041 · Cited by 8,527
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 1,994
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Weaver, F. M. (2009) · JAMA · doi:10.1001/jama.2008.929 · Cited by 1,525
Pharmacological Treatment of Parkinson Disease: A Review
Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,498
Neurostimulation for Parkinson's Disease with Early Motor Complications
Schuepbach, W. M. M., Rau, J., Knudsen, K., Volkmann, J., Krack, P., Timmermann, L., Hälbig, T. D., Hesekamp, H., Navarro, S. M., Meier, N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205158 · Cited by 1,430
Pallidal versus Subthalamic Deep-Brain Stimulation for Parkinson's Disease
Follett, K. A., Weaver, F. M., Stern, M., Hur, K., Harris, C. L., Luo, P., Marks, W. J., Rothlind, J., Sagher, O., Moy, C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907083 · Cited by 1,355
Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050
A Clinicopathologic Study of 100 Cases of Parkinson's Disease
Hughes, A. J., Daniel, S. E., Blankson, S., & Lees, A. J. (1993) · Archives of Neurology · doi:10.1001/archneur.1993.00540020018011 · Cited by 956
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901
de Rijk, M. C., Tzourio, C., Breteler, M. M., Dartigues, J. F., Amaducci, L., Lopez-Pousa, S., Manubens-Bertran, J. M., Alperovitch, A., & Rocca, W. A. (1997) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.1.10 · Cited by 833
A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease
Hernán, M. A., Takkouche, B., Caamaño‐Isorna, F., & Gestal‐Otero, J. J. (2002) · Annals of Neurology · doi:10.1002/ana.10277 · Cited by 818
Schenck, C. H., Boeve, B. F., & Mahowald, M. W. (2013) · Sleep Medicine · doi:10.1016/j.sleep.2012.10.009 · Cited by 814
Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease
Hughes, A. J., Daniel, S. E., & Lees, A. J. (2001) · Neurology · doi:10.1212/wnl.57.8.1497 · Cited by 807
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group (2000) · JAMA · doi:10.1001/jama.284.15.1931 · Cited by 767
Odekerken, V. J., van Laar, T., Staal, M. J., Mosch, A., Hoffmann, C. F., Nijssen, P. C., Beute, G. N., van Vugt, J. P., Lenders, M. W., Contarino, M. F., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70264-8 · Cited by 763
Gender differences in Parkinson's disease
Haaxma, C. A., Bloem, B. R., Borm, G. F., Oyen, W. J. G., Leenders, K. L., Eshuis, S., Booij, J., Dluzen, D. E., & Horstink, M. W. I. M. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.103788 · Cited by 741
Williams, A., Gill, S., Varma, T., Jenkinson, C., Quinn, N., Mitchell, R., Scott, R., Ives, N., Rick, C., Daniels, J., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70093-4 · Cited by 733
Olanow, C. W., Kieburtz, K., Odin, P., Espay, A. J., Standaert, D. G., Fernandez, H. H., Vanagunas, A., Othman, A. A., Widnell, K. L., Robieson, W. Z., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70293-x · Cited by 716
Bot, M., van den Munckhof, P., Bakay, R., Stebbins, G., & Verhagen Metman, L. (2017) · Stereotactic and Functional Neurosurgery · doi:10.1159/000475672 · Cited by 671
Systematic review of incidence studies of Parkinson's disease
Twelves, D., Perkins, K. S. M., & Counsell, C. (2003) · Movement Disorders · doi:10.1002/mds.10305 · Cited by 622
Dyskinesias and motor fluctuations in Parkinson's disease
Schrag, A., & Quinn, N. (2000) · Brain · doi:10.1093/brain/123.11.2297 · Cited by 600
Depression in Parkinson disease—epidemiology, mechanisms and management
Aarsland, D., Påhlhagen, S., Ballard, C. G., Ehrt, U., & Svenningsson, P. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.189 · Cited by 593
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561
Deep-Brain Stimulation for Parkinson's Disease
Okun, M. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmct1208070 · Cited by 541
Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome
Evans, A. H., Katzenschlager, R., Paviour, D., O'Sullivan, J. D., Appel, S., Lawrence, A. D., & Lees, A. J. (2004) · Movement Disorders · doi:10.1002/mds.20045 · Cited by 474
Parkinson risk in idiopathic REM sleep behavior disorder: Preparing for neuroprotective trials
Postuma, R. B., Gagnon, J.-F., Bertrand, J.-A., Génier Marchand, D., & Montplaisir, J. Y. (2015) · Neurology · doi:10.1212/wnl.0000000000001364 · Cited by 436
Wright Willis, A., Evanoff, B. A., Lian, M., Criswell, S. R., & Racette, B. A. (2010) · Neuroepidemiology · doi:10.1159/000275491 · Cited by 436
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
Nyholm, D., Nilsson Remahl, A. I. M., Dizdar, N., Constantinescu, R., Holmberg, B., Jansson, R., Aquilonius, S. M., & Askmark, H. (2005) · Neurology · doi:10.1212/01.wnl.0000149637.70961.4c · Cited by 432
PD MED Collaborative Group (2014) · The Lancet · doi:10.1016/s0140-6736(14)60683-8 · Cited by 407
Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome
Evans, A., Katzenschlager, R., Paviour, D. C., Appel‐Cresswell, S., Lawrence, A., & Lees, A. J. (2004) · UCL Discovery (University College London) · Cited by 401
Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism
Schrag, A., & Schott, J. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70411-2 · Cited by 384
Stocchi, F., Rascol, O., Kieburtz, K., Poewe, W., Jankovic, J., Tolosa, E., Barone, P., Lang, A. E., & Olanow, C. W. (2010) · Annals of Neurology · doi:10.1002/ana.22060 · Cited by 374
A comparison of clinical and pathological features of young‐ and old‐onset Parkinson's disease
Gibb, W. R. G., & Lees, A. J. (1988) · Neurology · doi:10.1212/wnl.38.9.1402 · Cited by 369
Incidence of parkinsonism and Parkinson disease in a general population: The Rotterdam Study
de Lau, L. M. L., Giesbergen, P. C. L. M., de Rijk, M. C., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2004) · Neurology · doi:10.1212/01.wnl.0000140706.52798.be · Cited by 360
Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?
Vingerhoets, F. J. G., Schulzer, M., Calne, D. B., & Snow, B. J. (1997) · Annals of Neurology · doi:10.1002/ana.410410111 · Cited by 359
Young‐onset Parkinson's disease revisited—clinical features, natural history, and mortality
Schrag, A., Ben‐Shlomo, Y., Brown, R., David Marsden, C., & Quinn, N. (1998) · Movement Disorders · doi:10.1002/mds.870130605 · Cited by 311
Kostic, V., Przedborski, S., Flaster, E., & Sternic, N. (1991) · Neurology · doi:10.1212/wnl.41.2_part_1.202 · Cited by 297
Suchowersky, O., Reich, S., Perlmutter, J., Zesiewicz, T., Gronseth, G., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000215437.80053.d0 · Cited by 280
Nonpharmacological treatments for patients with Parkinson's disease
Bloem, B. R., de Vries, N. M., & Ebersbach, G. (2015) · Movement Disorders · doi:10.1002/mds.26363 · Cited by 272
Dopamine Dysregulation Syndrome: An Overview of its Epidemiology, Mechanisms and Management
OʼSullivan, S. S., Evans, A. H., & Lees, A. J. (2009) · CNS Drugs · doi:10.2165/00023210-200923020-00005 · Cited by 265
Exercise for falls prevention in Parkinson disease: A randomized controlled trial
Canning, C. G., Sherrington, C., Lord, S. R., Close, J. C. T., Heritier, S., Heller, G. Z., Howard, K., Allen, N. E., Latt, M. D., Murray, S. M., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001155 · Cited by 262
Volpe, D., Signorini, M., Marchetto, A., Lynch, T., & Morris, M. E. (2013) · BMC Geriatrics · doi:10.1186/1471-2318-13-54 · Cited by 260
Risk of Parkinson's disease among first-degree relatives: A community-based study
Marder, K., Tang, M.-X., Mejia, H., Alfaro, B., Cote, L., Louis, E., Groves, J., & Mayeux, R. (1996) · Neurology · doi:10.1212/wnl.47.1.155 · Cited by 248
Suchowersky, O., Gronseth, G., Perlmutter, J., Reich, S., Zesiewicz, T., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000206363.57955.1b · Cited by 237
Kim, S. D., Allen, N. E., Canning, C. G., & Fung, V. S. C. (2013) · CNS Drugs · doi:10.1007/s40263-012-0012-3 · Cited by 234
Stress, depression and Parkinson's disease
Hemmerle, A. M., Herman, J. P., & Seroogy, K. B. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2011.09.035 · Cited by 225
Handwriting as an objective tool for Parkinson’s disease diagnosis
Rosenblum, S., Samuel, M., Zlotnik, S., Erikh, I., & Schlesinger, I. (2013) · Journal of Neurology · doi:10.1007/s00415-013-6996-x · Cited by 222
PROJECTED NUMBER OF PEOPLE WITH PARKINSON DISEASE IN THE MOST POPULOUS NATIONS, 2005 THROUGH 2030
Calabrese, V. P. (2007) · Neurology · doi:10.1212/01.wnl.0000271777.50910.73 · Cited by 213
Increased risk of Parkinson's disease in parents and siblings of patients
Payami, H., Larsen, K., Bernard, S., & Nutt, J. (1994) · Annals of Neurology · doi:10.1002/ana.410360417 · Cited by 211
Prognosis of Parkinson Disease: Risk of Dementia and Mortality: The Rotterdam Study
de Lau, L. M. L., Schipper, C. M. A., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2005) · Archives of Neurology · doi:10.1001/archneur.62.8.1265 · Cited by 211
Parkinson's disease: Evidence for environmental risk factors
Kieburtz, K., & Wunderle, K. B. (2013) · Movement Disorders · doi:10.1002/mds.25150 · Cited by 199
Physiotherapy versus placebo or no intervention in Parkinson's disease
Tomlinson, C. L., Patel, S., Meek, C., Clarke, C. E., Stowe, R., Shah, L., Sackley, C., Deane, K. H., Wheatley, K., & Ives, N. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002817 · Cited by 194
Impaired olfaction and other prodromal features in the Parkinson At‐Risk Syndrome study
Siderowf, A., Jennings, D., Eberly, S., Oakes, D., Hawkins, K. A., Ascherio, A., Stern, M. B., Marek, K., & the PARS Investigators (2012) · Movement Disorders · doi:10.1002/mds.24892 · Cited by 193
Parkinson's disease and anaesthesia
Nicholson, G., Pereira, A. C., & Hall, G. M. (2002) · British Journal of Anaesthesia · doi:10.1093/bja/aef268 · Cited by 193
The effect of onset age on the clinical features of Parkinson’s disease
Wickremaratchi, M. M., Ben‐Shlomo, Y., & Morris, H. R. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02514.x · Cited by 187
Dopamine Transporter Genetic Variants and Pesticides in Parkinson’s Disease
Ritz, B. R., Manthripragada, A. D., Costello, S., Lincoln, S. J., Farrer, M. J., Cockburn, M., & Bronstein, J. (2009) · Environmental Health Perspectives · doi:10.1289/ehp.0800277 · Cited by 184
Rolinski, M., Szewczyk-Krolikowski, K., Tomlinson, P. R., Nithi, K., Talbot, K., Ben-Shlomo, Y., & Hu, M. T. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306104 · Cited by 181
Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study)
Reid, W. G. J., Hely, M. A., Morris, J. G. L., Loy, C., & Halliday, G. M. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.232678 · Cited by 180
The nonmotor symptoms of Parkinson's disease—An overview
Lim, S., & Lang, A. E. (2010) · Movement Disorders · doi:10.1002/mds.22786 · Cited by 171
Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial
Sawada, H., Oeda, T., Kuno, S., Nomoto, M., Yamamoto, K., Yamamoto, M., Hisanaga, K., Kawamura, T., & for the Amantadine Study Group (2010) · PLoS ONE · doi:10.1371/journal.pone.0015298 · Cited by 168
Longitudinal follow-up of SWEDD subjects in the PRECEPT Study
Marek, K., Seibyl, J., Eberly, S., Oakes, D., Shoulson, I., Lang, A. E., Hyson, C., Jennings, D., & For The Parkinson Study Group PRECEPT Investigators (2014) · Neurology · doi:10.1212/wnl.0000000000000424 · Cited by 168
Stewart, T., Liu, C., Ginghină, C., Cain, K. C., Auinger, P., Cholerton, B., Shi, M. Y., & Zhang, J. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.12.007 · Cited by 161
Parkinson disease and smoking revisited: Ease of quitting is an early sign of the disease
Ritz, B., Lee, P.-C., Lassen, C. F., & Arah, O. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000879 · Cited by 160
Willis, A. W., Evanoff, B. A., Lian, M., Galarza, A., Wegrzyn, A., Schootman, M., & Racette, B. A. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwq303 · Cited by 159
Imaging insights into basal ganglia function, Parkinson's disease, and dystonia
Stoessl, A. J., Lehericy, S., & Strafella, A. P. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60041-6 · Cited by 159
Supplement 4: Canadian Guidelines on Parkinson's Disease
Grimes, D., Gordon, J., Snelgrove, B., Lim-Carter, I., Fon, E. A., Martin, W. R. W., Wieler, M., Suchowersky, O., Rajput, A. H., Lafontaine, A. L., et al. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s031716710001516x · Cited by 157
Self-citationRacial differences in the diagnosis of Parkinson's disease
Dahodwala, N. A., Siderowf, A. D., Xie, M., Noll, E. L., Stern, M., & Mandell, D. S. (2009) · Movement Disorders · doi:10.1002/mds.22557 · Cited by 150
Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations
Sato, K.-I., Hatano, T., Yamashiro, K., Kagohashi, M., Nishioka, K., Izawa, N., Mochizuki, H., Hattori, N., Mori, H., & Mizuno, Y. (2006) · Movement Disorders · doi:10.1002/mds.20993 · Cited by 149
Erro, R., Schneider, S. A., Stamelou, M., Quinn, N. P., & Bhatia, K. P. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-310256 · Cited by 148
A clinical genetic study of Parkinson's disease
Lazzarini, A. M., Myers, R. H., Zimmerman, T. R., Mark, M. H., Golbe, L. I., Sage, J. I., Johnson, W. G., & Duvoisin, R. C. (1994) · Neurology · doi:10.1212/wnl.44.3_part_1.499 · Cited by 137
Dopamine Agonist Withdrawal Syndrome: Implications for Patient Care
Nirenberg, M. J. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0090-z · Cited by 134
Modeling Lewy pathology propagation in Parkinson's disease
Luk, K. C., & Lee, V. M. ‐. (2013) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70022-1 · Cited by 132
Advances in imaging in Parkinson's disease
Stoessl, A. J., Martin, W. R. W., McKeown, M. J., & Sossi, V. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70214-9 · Cited by 130
Ceravolo, R., Frosini, D., Rossi, C. A., & Bonuccelli, U. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70847-8 · Cited by 129
Motor response complications and the function of striatal efferent systems.
Chase, T. N., Mouradian, M. M., & Engber, T. M. (1993) · PubMed · Cited by 122
Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease
Liu, R., Umbach, D. M., Peddada, S. D., Xu, Z., Tröster, A. I., Huang, X., & Chen, H. (2015) · Neurology · doi:10.1212/wnl.0000000000001609 · Cited by 121
Early-onset vs. Late-onset Parkinson’s disease: A Clinical-pathological Study
Ferguson, L. W., Rajput, A. H., & Rajput, A. (2015) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2015.244 · Cited by 118
Bladder, Bowel, and Sexual Dysfunction in Parkinson's Disease
Sakakibara, R., Kishi, M., Ogawa, E., Tateno, F., Uchiyama, T., Yamamoto, T., & Yamanishi, T. (2011) · Parkinson's Disease · doi:10.4061/2011/924605 · Cited by 118
Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations
Marras, C., Lang, A. E., Krahn, M. D., TOMLINSON, G. A., Naglie, G., & The Parkinson Study Group (2004) · Movement Disorders · doi:10.1002/mds.10642 · Cited by 112
Epidemiology, diagnosis and differential diagnosis in Parkinson's disease tremor
Baumann, C. R. (2011) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70029-3 · Cited by 110
Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7‐year experience
Zibetti, M., Merola, A., Artusi, C. A., Rizzi, L., Angrisano, S., Reggio, D., Angelis, C. D., Rizzone, M. G., & Lopiano, L. (2013) · European Journal of Neurology · doi:10.1111/ene.12309 · Cited by 107
Evidence-based treatment of voice and speech disorders in Parkinson disease
Mahler, L. A., Ramig, L. O., & Fox, C. (2015) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0000000000000151 · Cited by 101
Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic
Pondal, M., Marras, C., Miyasaki, J., Moro, E., Armstrong, M. J., Strafella, A. P., Shah, B. B., Fox, S., Prashanth, L. K., Phielipp, N., et al. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302684 · Cited by 99
Treatment of advanced Parkinson's disease
Giugni, J. C., & Okun, M. S. (2014) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000118 · Cited by 94
Nyholm, D., Lennernäs, H., Gomes–Trolin, C., & Aquilonius, S. (2002) · Clinical Neuropharmacology · doi:10.1097/00002826-200203000-00006 · Cited by 93
Does clinical rapid eye movement behavior disorder predict worse outcomes in Parkinson’s disease?
Lavault, S., Leu‐Semenescu, S., du Montcel, S. T., Cock, V. C. D., Vidailhet, M., & Arnulf, I. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5482-y · Cited by 93
Acute and subacute drug-induced movement disorders
Burkhard, P. R. (2013) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70027-0 · Cited by 90
Nonmotor Symptoms and Subthalamic Deep Brain Stimulation in Parkinson’s Disease
Kim, H., Jeon, B. S., & Paek, S. H. (2015) · Journal of Movement Disorders · doi:10.14802/jmd.15010 · Cited by 87
Progression of Parkinson Disease
Jankovic, J. J. (2005) · Archives of Neurology · doi:10.1001/archneur.62.3.351 · Cited by 84
Clinical and pharmacological differences in early‐ versus late‐onset Parkinson's disease
Gómez-Arévalo, G., Jorge, R. E., García, S., Scipioni, O., & Gershanik, O. S. (1997) · Movement Disorders · doi:10.1002/mds.870120303 · Cited by 76
Zibetti, M., Merola, A., Ricchi, V., Marchisio, A., Artusi, C. A., Rizzi, L., Montanaro, E., Reggio, D., Angelis, C., Rizzone, M. G., et al. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6597-0 · Cited by 74
Ghaffari, B. D., & Kluger, B. M. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0451-y · Cited by 73
Motor complications in an incident Parkinson's disease cohort
SCOTT, N. W., Macleod, A. D., & Counsell, C. E. (2015) · European Journal of Neurology · doi:10.1111/ene.12751 · Cited by 69
Treatment of dysautonomia associated with Parkinson's disease
Mostile, G., & Jankovic, J. J. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70820-x · Cited by 68
Treatment of Parkinson’s disease in the advanced stage
Ossig, C., & Reichmann, H. (2013) · Journal of neural transmission · doi:10.1007/s00702-013-1008-y · Cited by 59
A 5-Year Follow-up Study on the Relationship between Obstructive Sleep Apnea and Parkinson Disease
Sheu, J., Lee, H., Lin, H., Kao, L., & Chung, S. (2015) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.5274 · Cited by 57
Rahimi, F., Samotus, O., Lee, J., & Jog, M. (2015) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.240 · Cited by 55
Self-citationOthman, A. A., & Dutta, S. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12324 · Cited by 50
α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of parkinson disease
Covy, J. P., & Giasson, B. I. (2011) · NeuroToxicology · doi:10.1016/j.neuro.2011.01.003 · Cited by 44
van Laar, T. (2003) · CNS Drugs · doi:10.2165/00023210-200317070-00002 · Cited by 43
Tremor revisited: Treatment of PD tremor
Jiménez, M. C., & Vingerhoets, F. J. G. (2011) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70030-x · Cited by 43
Modern treatment in Parkinson’s disease, a personal approach
Reichmann, H. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-015-1441-1 · Cited by 36
Gershanik, O. S., & Jenner, P. G. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03593.x · Cited by 35
Time to change the blind men and the elephant approach to Parkinson disease?
Racette, B. A., & Willis, A. W. (2015) · Neurology · doi:10.1212/wnl.0000000000001739 · Cited by 34
Parkinson's disease and anaesthesia
Gray, H., Wilson, S., Sidebottom, P., & Nicholson, G. (2003) · British Journal of Anaesthesia · doi:10.1093/bja/aeg549 · Cited by 32
Rocchi, C., Pierantozzi, M., Galati, S., Chiaravalloti, A., Pisani, V., Prosperetti, C., Lauretti, B., Stampanoni Bassi, M., Olivola, E., Schillaci, O., et al. (2015) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12437 · Cited by 31
Rahimi, F., Samotus, O., Lee, J., et al. (2015) · PubMed · doi:10.7916/d8bp0270 · Cited by 29
Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions
Ramirez‐Zamora, A., & Molho, E. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.868306 · Cited by 27
Incidence of parkinsonism and Parkinson disease in a general population: The Rot terdam Study
Rotterdam (2005) · Dkgest of the World Latest Medical Information · Cited by 27
Solla, P., Fasano, A. A., Cannas, A., Mulas, C. S., Marrosu, M. G., Lang, A. E., & Marrosu, F. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.05.018 · Cited by 26
Has drug therapy changed the natural history of Parkinson’s disease?
Clarke, C. E. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5716-z · Cited by 12
Cited by
Modeling Parkinson’s Disease With the Alpha-Synuclein Protein
Gómez-Benito, M., Granado, N., García-Sanz, P., Michel, A., Dumoulin, M., & Moratalla, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00356 · Cited by 437
Biomedical Applications and Bioavailability of Curcumin—An Updated Overview
Sohn, S.-I., Priya, A., Balasubramaniam, B., Muthuramalingam, P., Sivasankar, C., Selvaraj, A., Valliammai, A., Jothi, R., & Pandian, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122102 · Cited by 305
Clinical Features of Parkinson’s Disease: The Evolution of Critical Symptoms
Váradi, C. (2020) · Biology · doi:10.3390/biology9050103 · Cited by 196
Loh, H. W., Ooi, C. P., Palmer, E., Barua, P. D., Dogan, S., Tuncer, T., Baygin, M., & Acharya, U. R. (2021) · Electronics · doi:10.3390/electronics10141740 · Cited by 144
“…criteria of bradykinesia with at least one feature of rest tremor or rigidity, symptoms closely linked to dopaminergic neurons, and the absence of certain exclusion criteria and presence of supportive criteria, the main being a clear and dramatic beneficial response to dopaminergic therapy [15,16].”
BackgroundTargeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases
Anthony, D. P., Hegde, M., Shetty, S. S., Rafic, T., Mutalik, S., & Rao, B. S. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119326 · Cited by 110
Metadata
- Authors
- Rizek, P., Kumar, N., & Jog, M. S.
- Venue
- Canadian Medical Association Journal
- Publisher
- CMA Impact Inc.
- Published
- 2016-05-24
- Volume
- 188
- Issue
- 16
- Pages
- 1157-1165
- ISSN
- 0820-3946 (ISSN-L)
- 1488-2329
- OpenAlex
- W2403629665
- Cited by
- 447
- References
- 117
- FWCI
- 11.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.